<p>SAN DIEGO, Sept. 29, 2023 (GLOBE NEWSWIRE) — Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeuti
<p>Pivot (invalidation): 18.25 Our preference Long positions above 18.25 with targets at 20.50 & 21.60 in extension. Alternative scenario Below 18.25 look for further downside with 17.50 &#
Leave a Comment